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Aims Midwall myocardial fibrosis on cardiovascular magnetic resonance (CMR) is a marker of early ventricular decompen-
sation and adverse outcomes in aortic stenosis (AS). We aimed to develop and validate a novel clinical score using
variables associated with midwall fibrosis.
Methods
and results
One hundred forty-seven patients (peak aortic velocity (Vmax) 3.9 [3.2,4.4] m/s) underwent CMR to determine midwall
fibrosis (CMR cohort). Routine clinical variables that demonstrated significant association with midwall fibrosis were
included in a multivariate logistic score. We validated the prognostic value of the score in two separate outcome
cohorts of asymptomatic patients (internal: n ¼ 127, follow-up 10.3 [5.7,11.2] years; external: n ¼ 289, follow-up
2.6 [1.6,4.5] years). Primary outcome was a composite of AS-related events (cardiovascular death, heart failure, and
new angina, dyspnoea, or syncope). The final score consisted of age, sex, Vmax, high-sensitivity troponin I concentration,
and electrocardiographic strain pattern [c-statistic 0.85 (95% confidence interval 0.78–0.91), P, 0.001; Hosmer–
Lemeshow x2 ¼ 7.33, P ¼ 0.50]. Patients in the outcome cohorts were classified according to the sensitivity and
specificity of this score (both at 98%): low risk (probability score ,7%), intermediate risk (7–57%), and high risk
(.57%). In the internal outcome cohort, AS-related event rates were .10-fold higher in high-risk patients compared
with those at low risk (23.9 vs. 2.1 events/100 patient-years, respectively; log rank P, 0.001). Similar findings were
observed in the external outcome cohort (31.6 vs. 4.6 events/100 patient-years, respectively; log rank P, 0.001).
Conclusion We propose a clinical score that predicts adverse outcomes in asymptomatic AS patients and potentially identifies
high-risk patients who may benefit from early valve replacement.
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Keywords Aortic stenosis † Midwall myocardial fibrosis † Cardiovascular magnetic resonance imaging † High-sensitivity
troponin I concentrations † Electrocardiogram strain
Introduction
In response to aortic stenosis (AS), left ventricular (LV) hypertrophy
initially occurs as a compensatory response to maintain wall stress
and cardiac output. Ultimately, the LV decompensates and heart
failure ensues. The transition from adaptive LV hypertrophy to heart
failure is characterized by myocyte death and myocardial fibrosis1 –3
and is an important determinant of symptoms and adverse clinical
outcomes. Myocardial fibrosis can be detected non-invasively using
cardiovascular magnetic resonance (CMR), and increasing evidence
has demonstrated the presence of midwall fibrosis as an early mark-
er of ventricular decompensation and predictor of adverse cardio-
vascular outcomes in patients with AS.4– 9
Despite its potential prognostic value, the widespread clinical
utility of CMR is sometimes limited by cost, availability, and patient
suitability. We have recently demonstrated two alternative and
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more widely available markers of LV decompensation that are close-
ly associated with the presence of midwall fibrosis.10,11 In separate
studies, high-sensitivity plasma cardiac troponin I (cTnI) concentra-
tions and the presence of LV hypertrophy with strain pattern on the
electrocardiogram (ECG strain) were both independently asso-
ciated with midwall fibrosis on CMR and adverse cardiovascular
events, over and above conventional prognostic markers in
AS.10,11 While high-sensitivity cTnI was a sensitive marker (100%)
of midwall myocardial fibrosis, the ECG strain pattern was very spe-
cific (99%). The integration of these objective markers of LV decom-
pensation into a clinical predictive score therefore represents a
potentially attractive strategy of risk stratifying asymptomatic
patients with AS and guiding the optimal timing of aortic valve
replacement (AVR).
Using a novel approach, we aimed to develop a predictive score
comprising variables associated with midwall myocardial fibrosis on
CMR: a pathophysiologically relevant marker of early decompensa-
tion and adverse outcomes in AS. We then validated the prognostic
impact of this clinical score in two large independent cohorts of
asymptomatic patients with AS.
Methods
Patient populations
Three cohorts of patients were used in the study. A cohort of patients
undergoing CMR was used to develop the clinical score to determine
the probability of midwall myocardial fibrosis (CMR derivation cohort).
This score was based on simple and widely available cardiac investiga-
tions. The prognostic value of this clinical score was then validated in
two independent outcome cohorts of asymptomatic patients with an
ejection fraction of .50%: an internal outcome cohort from the south-
east of Scotland and an external outcome cohort from the Bichat Hos-
pital, Paris. The study was conducted in accordance with the Declaration
of Helsinki and was approved by the local research ethics committee.
Written informed consent was obtained in all patients.
Cardiovascular magnetic resonance derivation cohort
The CMR derivation cohort consisted of stable patients with
mild-to-severe AS. Patients were recruited from the outpatient clinics at
the Edinburgh Heart Centre from March 2012 (clinicalTrials.gov identifier
NCT01755936). Patients who had other significant valvular heart disease
(≥ moderate), contraindications to CMR or cardiomyopathies (acquired
or inherited) were excluded. As this study aimed to identify variables of
midwall myocardial fibrosis due to AS, we excluded patients with previous
myocardial infarction based on clinical history and confirmed on CMR.
Blood samples were taken at the time of CMR and clinical assessment.
Internal outcome cohort
This internal outcome cohort consisted of patients with AS initially re-
cruited into the Scottish Aortic Stenosis and Lipid Lowering Trial, Im-
pact of REgression study. In brief, 155 asymptomatic patients were
recruited between March 2001 and April 2002 to investigate the effects
of intensive lipid-lowering therapy on AS progression.12
External outcome cohort
The external outcome cohort comprised of asymptomatic patients with
at least mild AS from the COFRASA and GENERAC studies (clinical-
Trials.gov numbers NCT00338676 and NCT00647088, respectively).
These patients were prospectively recruited since November 2006.
Exclusion criteria were AS due to rheumatic valvular disease or radio-
therapy, previous infective endocarditis, other significant valvular dis-
eases (≥moderate), and severe respiratory or renal insufficiency.
Electrocardiography
A standard 12-lead ECG was performed in all patients. Electrocardio-
gram strain was diagnosed with the Romhilt-Estes point system (≥5
points)13 and the presence of ≥1 mm concave downsloping ST depres-
sion with asymmetrical T-wave inversion in the lateral leads.14
Echocardiography
All patients underwent comprehensive echocardiography to determine
AS severity. Peak aortic jet velocity (Vmax) and the mean pressure gradi-
ent were determined by velocity time integral spectral Doppler, and the
aortic valve area estimated using the continuity equation. The severity
was assessed and classified according to the European Association of
Echocardiography/American Society of Echocardiography guidelines.15
High-sensitivity cardiac troponin I and
natriuretic peptide assays
Plasma cTnI concentrations were determined across the three cohorts
using a high-sensitivity assay (ARCHITECTSTAT, Abbott Laboratories, IL,
USA). The lower limit of detection for this assay was 1.2 ng/L and the
concentration at 10% inter-assay imprecision was 4.7 ng/L.16 Concen-
trations lower than the detection levels were assigned a value of
1.2 ng/L. In the CMR derivation cohort, plasma brain natriuretic peptide
(BNP) concentrations were determined using the Triage BNP assay
(Biosite Inc., San Diego, CA, USA).17 In the internal and external
outcome cohorts, plasma N-terminal pro-BNP concentrations were
measured using the Elecsys 2010 analyzer (Roche Diagnostics Ltd,
Lewes, UK).18 For both BNP assays, concentrations lower than the
manufacturer-reported lower limit of detection were assigned the low-
est value (5 pg/mL).
Cardiovascular magnetic resonance in the
cardiovascularmagnetic resonance derivation
cohort
Cardiovascular magnetic resonance was performed using a 3T scanner
(MAGNETOM Verio, Siemens AG, Healthcare Sector, Germany).
Short-axis cines from the mitral valve annulus to the apex were used
to assess LV volume, function, and mass (balanced steady-state free pre-
cision sequence; 8 mm parallel slices with 2 mm gap). All measurements
were indexed to body surface area (Argus Ventricular Function, Sie-
mens AG Healthcare Sector, Erlangen, Germany). Cardiovascular mag-
netic resonance LV longitudinal function was assessed using a method
previously described.11
The assessment of focal midwall myocardial fibrosis was performed
using late gadolinium enhancement (LGE), 15 min following 0.1 mmol/kg
of gadobutrol (Gadovist/Gadavist, Bayer Pharma AG, Germany). Two
approaches were used: an inversion recovery fast gradient-echo
sequence and a phase-sensitive inversion recovery sequence, per-
formed in two phase-encoding directions to differentiate true late
enhancement from artefact. The inversion time was optimized to
achieve satisfactory nulling of the myocardium for the inversion-
recovery images. Midwall LGE was determined qualitatively by two
independent and experienced operators (C.W.L.C. and M.R.D.).
Clinical outcomes
The primary outcome of the study was AS-related events: a composite of
cardiovascular mortality, congestive heart failure, and new symptoms of
angina, syncope, or dyspnoea. The secondary outcomes were all-cause
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mortality and cardiovascular mortality. All events in the internal outcome
cohort were adjudicated from the General Register of Scotland and veri-
fied by two independent investigators. Any discrepancy was resolved by
consensus. In the external outcome cohort, events were adjudicated by
experienced cardiologists blinded to any biological or ECG information.
Patients in the internal and external outcome cohorts were followed until
September 2012 and December 2014, respectively and events were
censored at the time of last patient contact or at the time of AVR.
Statistical analysis
Baseline characteristics were reported as percentages for categorical vari-
ables, mean+ standard deviation or median (inter-quartile range) for
continuous variables as appropriate. The distribution of all continuous
variables was tested for normality using the Shapiro–Wilk test. Statistical
analyses were performed using SPSS version 20 (IBM Corp., Armonk, NY,
USA) and GraphPad Prism version 5.0 (GraphPad Software, San Diego,
CA, USA). Statistical significance was taken as a two-sided P, 0.05.
Establishing determinants of midwall myocardial fibrosis
In the CMR derivation cohort, clinically relevant variables that demon-
strated univariate association with midwall myocardial fibrosis
(P, 0.20) were selected in the multivariate logistic model. Subsequent-
ly, backward elimination method was used to establish a best-fitting
parsimonious model, providing the basis for the score. The diagnostic
performance of the clinical score was assessed using the c statistic for
discrimination (area under the receiver operating curve) and the Hos-
mer–Lemeshow goodness of fit for calibration. We then identified
score thresholds at 98% sensitivity and 98% specificity for midwall
myocardial fibrosis, accepting a combined false-positive and -negative
rate of ,5%. These values would define the risk categories of patients
in the outcome cohorts.
Validation of clinical score and cardiovascular outcomes
Using our clinical score, the predicted probability (P) for midwall myo-
cardial fibrosis was calculated for each patient in the internal and exter-
nal outcome cohorts, according to the equation: P = expy/[1 + expy],
where y = b0 +
∑
biXi, where b0 is the constant of the logistic equa-
tion, bi is the regression coefficient of each variable, and Xi is the clinical
model. In practice, the clinical score and the corresponding risk category
for each patient were obtained easily using our online calculator (see
Aortic Stenosis Risk Calculator, Supplementary material online) or a
nomogram (Figure 1). The clinical score is also available in the mobile
app Calculate by QxMD on iOS, Android and Windows (http://qx.
md/calculate) and on the web at qxmd.com/as-risk-score.
Patients with scores less than the threshold at 98% sensitivity for mid-
wall myocardial fibrosis were classified as low risk. Conversely, patients
with scores greater than the threshold at 98% specificity for midwall
myocardial fibrosis were classified as high risk. All others were at inter-
mediate risk. Time-to-first event survival curves associated with the dif-
ferent risk categories were estimated using the Kaplan–Meier method
and compared with the log-rank test.
Results
Cardiovascular magnetic resonance
derivation cohort
One hundred and sixty-six patients with AS were recruited in the
CMR derivation cohort. We excluded 15 patients with myocardial
infarction and 5 patients without blood samples (1 patient with myo-
cardial infarction did not have blood samples). Compared with
patients without midwall fibrosis (n ¼ 103), those with midwall
fibrosis (n ¼ 44) had more severe AS and elevated markers of
LV decompensation (P, 0.001 for all; Table 1). Thirty-seven
patients in the CMR derivation cohort had symptoms consistent
with severe AS.
The final clinical score of age, sex, high-sensitivity cTnI concentra-
tions (log10 transformed), Vmax (loge transformed), and ECG strain
demonstrated excellent discrimination (c statistics ¼ 0.85; 95% con-
fidence interval 0.78–0.91; P, 0.001) and calibration (Hosmer–
Lemeshow x2 ¼ 7.33; P ¼ 0.50; Table 2), and it outperformed other
determinants of midwall myocardial fibrosis (Table 3). The risk prob-
abilities that corresponded to 98% sensitivity and 98% specificity for
midwall fibrosis were 7.0 and 57.0%, respectively. On this basis, 14%
of patients (n ¼ 21) in the CMR derivation cohort were at low risk
of midwall myocardial fibrosis (risk score , 7.0%) and 19% (n ¼ 28)
at high risk (risk score .57.0%). Among those at intermediate
risk (n ¼ 98), 18% had midwall myocardial fibrosis on CMR. Of
note, the clinical score correlated well with diastolic function
(r ¼ 0.31; P, 0.001), CMR longitudinal function (r ¼ 20.42;
P, 0.001), and fibrosis volume assessed using myocardial T1 map-
ping (r ¼ 0.66; see Supplementary material online).
Association between clinical score
and adverse events
Internal outcome cohort
In this cohort, 127 asymptomatic patients were analysed (69 [62,75]
years, 70% males, Vmax 3.4 [2.9,4.0] m/s) after excluding patients
without blood samples (n ¼ 24). Using the two risk thresholds
established from the CMR derivation cohort, 13% of the patients
(n ¼ 17) in the internal outcome cohort were classified as
low risk and 15% (n ¼ 19) as high risk. While no low-risk patients
had Vmax ≥4.0 m/s, 42% of high-risk patients had Vmax between
3.0 and 3.9 m/s (Table 4).
There were 62 AS-related events (cardiovascular mortality,
n ¼ 26; congestive heart failure and new symptoms, n ¼ 36) over
10.3 [5.7,11.2] years of follow-up (704.6 patient-years; 8.8 events/
100 patient-years). In low-risk patients, only three AS-related events
were observed. Conversely, high-risk patients had over a 10-fold
increase in the AS-related event rate (23.9 vs. 2.1 events/100
patient-years in low-risk patients; log rank P, 0.001; Figure 2;
Table 4), which all occurred early and within the first 5 years.
Similar findings were observed with mortality rates. Forty-six
patients died (26 from cardiovascular causes) during follow-up. In
the low-risk group, there were no cardiovascular deaths during
the entire period of follow-up. Three patients died from non-cardiac
causes with no deaths within the first 5 years. By comparison,
mortality rates were 7-fold higher in high-risk patients (13.0 vs.
2.1 all-cause deaths/100 patient-years in low-risk patients; log rank
P, 0.001; Figure 3), and cardiovascular causes accounted for
more than two-thirds of the deaths.
External outcome cohort
A total of 289 patients were analysed (74 [67,80] years, 72% males,
Vmax 3.0 [2.5,3.6] m/s), after excluding patients without blood
samples (n ¼ 18) or interpretable ECGs (n ¼ 25; Table 5). In this
cohort, 16% (n ¼ 45) and 8.0% (n ¼ 23) of the patients were
classified as low and high risk, respectively. Two low-risk patients
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had Vmax ¼ 4.0 m/s while 30% of high-risk patients had Vmax
between 3.0 and 3.9 (Table 4). Over 2.6 [1.6,4.5] years of follow-up
(854.9 patient-years), there were 76 AS-related events (cardio-
vascular deaths, n ¼ 9; congestive heart failure and new symptoms,
n ¼ 67) and an event rate similar to the internal outcome cohort
(8.9 AS-related events/100 patient-years). The prognosis of low-risk
patients was very favourable: only 7 events throughout the follow-
up with no events in the first 2 years. Conversely, high-risk patients
had substantially worse outcomes (31.6 vs. 4.6 AS-related events/
100 patient-years in low-risk patients; log-rank test P, 0.001;
Figure 2), and these events occurred very early (median time to
event of 1.5 years). Compared with the internal outcome cohort,
the external outcome cohort had a much shorter duration of
follow-up and not unexpectedly, a considerably lower mortality
rate that precluded further detailed analysis.
Incremental prognostic value of clinical
score
We examined in greater detail the prognostic value of the clinical
score. Addition of high-sensitivity cTnI and ECG strain in the
score provided incremental prognostic value, over and above Vmax,
Figure 1 Nomogram for aortic stenosis clinical score. The risk probability can be also calculated using a nomogram. For example, a 50-year-old
female patient with peak aortic jet velocity of 4.0 m/s, high-sensitivity cardiac troponin concentration of 30 ng/L and electrocardiogram strain
pattern would have a risk probability of 78% (high risk).
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Table 2 Clinical determinants of midwall myocardial fibrosis
Variable Univariate Clinical modela
Regression coefficient
(standard error)
P Regression coefficient
(standard error)
P
Age (years) 0.021 (0.016) 0.19 0.047 (0.027) 0.08
Male 0.692 (0.400) 0.08 1.356 (0.651) 0.04
SBP (mmHg) 0.007 (0.008) 0.64 – –
Presence of CAD 0.412 (0.370) 0.27 – –
Vmax (m/s)
b 3.514 (0.922) ,0.001 2.319 (1.282) 0.07
hsTnI concentration (ng/L)c 2.133 (0.486) ,0.001 0.935 (0.604) 0.12
BNP concentration (pg/mL)b 1.056 (0.424) 0.01 – –
ECG strain 4.364 (1.046) ,0.001 3.616 (1.145) 0.002
Constant – – 29.387 (2.801) 0.001
For abbreviations, see Table 1.
aBrain natriuretic peptide was selected in the initial multivariate model; but it was not retained in the final clinical score using backward elimination.
bValues were loge transformed.
cValues were log10 transformed.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of patients in the cardiovascular magnetic resonance cohort
All patients
(N5 147)
No midwall myocardial
fibrosis (N5 103)
Midwall myocardial
fibrosis (N 5 44)
P
Clinical characteristics
Age (years) 70 [63,76] 70 [63,76] 71 [65,78] 0.42
Male, n (%) 99 (68) 66 (67) 33 (70) 0.20
Diabetes mellitus, n (%) 21 (14) 15 (15) 6 (13) 0.64
CAD, n (%) 47 (32) 29 (29) 18 (38) 0.34
SBP (mmHg) 151+21 151+22 153+19 0.41
hsTnI concentration (ng/L) 6.0 [3.6,11.6] 4.6 [3.2,8.0] 10.8 [6.6,26.5] ,0.001
BNP concentration (pg/mL) 24.7 [10.4,53.1] 21.8 [7.5,43.4] 34.4 [12.4,87.5] 0.01
ECG strain, n (%) 22 (15) 0 22 (46) ,0.001
Echocardiogrphy
Vmax (m/s) 3.9 [3.2,4.4] 3.7 [2.9,4.2] 4.1 [3.8,4.6] ,0.001
MPG (mmHg) 33 [22,43] 29 [17,40] 37 [29,50] ,0.001
AVA (cm2) 0.88 [0.73,1.11] 0.96 [0.74,1.20] 0.81 [0.73,0.91] 0.008
LVMi (g/m
2) 122+32 116+29 137+34 ,0.001
Diastolic function (E/e′) 12.6 [10.1,16.7] 11.7 [8.9,15.2] 14.5 [12.3,19.9] ,0.001
CMR
EDVi (mL/m
2) 69 [61,78] 68 [60,76] 72 [65,88] 0.03
ESVi (mL/m
2) 23 [18,27] 22 [18,26] 24 [20,30] 0.08
SVi (mL/m
2) 47 [41,54] 46 [40,53] 49 [43,58] 0.05
LVEF (%) 67 [63,71] 68 [64,71] 67 [63,71] 0.55
Longitudinal function (mm) 12.3+2.9 13.0+2.6 10.9+3.1 ,0.001
LVMi (g/m
2) 87 [73,99] 80 [67,91] 101 [93,118] ,0.001
LVM/EDV (g/mL) 1.26+0.27 1.18+0.24 1.42+0.27 ,0.001
CAD, coronary artery disease; SBP, systolic blood pressure; hsTnI, high-sensitivity cardiac troponin I; BNP, brain natriuretic peptide; NT-proBNP, N-terminal proBNP; ECG strain,
electrocardiographic left ventricular hypertrophy with strain; Vmax, peak aortic jet velocity; MPG, mean pressure gradient; AVA, aortic valve area; LVMi, indexed left ventricular mass;
EDVi, indexed end-diastolic volume; ESVi, indexed end-systolic volume; SVi, indexed stroke volume; LVEF, left ventricular ejection fraction.
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Table 3 Performance of determinants associated with midwall myocardial fibrosis
Discrimination Calibration
Hosmer–Lemeshow
goodness-of-fit test
c statistics (95% CI) P x2 P
Vmax 0.70 (0.62–0.79) ,0.001 6.5 0.58
BNP concentration 0.63 (0.52–0.74) 0.016 13.5 0.06
hsTnI concentration 0.76 (0.68–0.85) ,0.001 15.0 0.06
ECG strain 0.71 (0.62–0.81) ,0.001 NA NA
Clinical scorea 0.85 (0.78–0.91) ,0.001* 7.3 0.50
For abbreviations, see Table 1.
aThe clinical score consisted of age, sex, Vmax, hsTnI concentrations, and ECG strain.
*P, 0.05 when compared with Vmax, BNP concentration and ECG strain; P ¼ 0.07 when compared with hsTnI concentration.
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Table 4 Relevant characteristics of patients in the cardiovascular magnetic resonance and outcome cohorts risk
stratified by probabilities of midwall fibrosis
Low risk (probability <7%) CMR cohort (N 5 21) Internal outcome cohort (N 5 17) External outcome cohort (N 5 45)
Age (years) 63 [48,69] 57 [49,66] 70 [61,74]
Males, n (%) 3 (14) 3 (18) 4 (9)
Vmax (m/s) 2.8 [2.5,3.2] 3.0 [2.7,3.4] 2.6 [2.4,2.9]
ECG strain, n (%) 0 0 0
hsTnI concentration (ng/L) 2.1 [1.5,4.0] 5.4 [4.0,6.6] 4.1 [3.0,6.4]
Patients with Vmax 3.0–3.9 m/s, n (%) 5 (24) 10 (59) 6 (13)
Patients with Vmax ≥4.0 m/s, n (%) 1 (5) 0 2 (4)
AS-related events, n (%) NA 3 (18) 7 (16)
Intermediate risk (probability 7–57%) CMR cohort (N 5 98) Internal outcome cohort (N 5 91) External outcome cohort (N 5 221)
Age (years) 71 [66,77] 69 [63,75] 75 [67,80]
Males, n (%) 74 (76) 71 (78) 186 (84)
Vmax (m/s) 3.8 [3.3,4.2] 3.3 [2.8,4.0] 3.1 [2.6,3.5]
ECG strain, n (%) 0 0 0
hsTnI concentration (ng/L) 5.3 [3.8,9.5] 7.6 [5.8,12.2] 7.0 [5.0,11.0]
Patients with Vmax 3.0–3.9 m/s, n (%) 47 (48) 40 (44) 96 (43)
Patients with Vmax ≥4.0 m/s, n (%) 37 (38) 24 (26) 27 (12)
AS-related events, n (%) NA 47 (52) 56 (25)
High risk (probability >57%) CMR cohort (N 5 28) Internal outcome cohort (N 5 19) External outcome cohort (N 5 23)
Age (years) 71 [62,78] 75 [66,77] 79 [72,84]
Males, n (%) 22 (79) 15 (79) 19 (83)
Vmax (m/s) 4.6 [4.1,5.1] 4.1 [3.5,4.4] 3.9 [3.1,5.4]
ECG strain, n (%) 22 (92) 19 (100) 17 (74)
hsTnI concentration (ng/L) 25.2 [10.1,46.7] 17.3 [10.5,29.6] 14.0 [9.0,21.0]
Patients with Vmax 3.0–3.9 m/s, n (%) 4 (14) 8 (42) 7 (30)
Patients with Vmax ≥4.0 m/s, n (%) 24 (86) 10 (53) 11 (48)
AS-related events, n (%) NA 12 (63) 13 (57)
For abbreviations, see Table 1.
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age and sex (global x2 increased from 117 to 133; P ¼ 0.03;
Figure 3). In particular, across the two outcome cohorts, similar im-
provement in risk stratification was observed in patients stratified by
either median age or sex (log-rank test P, 0.001 for all analyses;
Figure 4).
Among patients with at least moderate AS (either Vmax ≥3.0 m/s
or aortic valve area ≤1.5 cm2), the clinical score further improved
risk-stratification and identified patients with very low- and
high-event rates (log rank P, 0.001 for both; Figure 5). Of note,
the remaining patients at intermediate risk had an event rate almost
identical to the natural history of the patients with moderate and se-
vere AS (green dotted line; Figure 5).
Discussion
In a large CMR cohort of patients with AS, we have proposed the
first clinical score consisting of variables associated with midwall
myocardial fibrosis, an early and important marker of LV decompen-
sation. This simple clinical score demonstrated excellent diagnostic
performance for midwall myocardial fibrosis on CMR. Using the no-
vel thresholds and across .400 asymptomatic patients (1560
patient-years), those at high risk (11% of patients in both outcome
cohorts) had extremely poor outcomes while low-risk patients
(16%) had very favourable prognosis. The clinical score has demon-
strated important prognostic information in identifying patients who
Figure 2 Aortic stenosis-related events stratified according to the risk of midwall myocardial fibrosis in the internal outcome cohort (A) and
external outcome cohort (B).
Figure 3 Cardiovascular (A) and all-cause mortality (B) in the internal outcome cohort.
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either may benefit from early AVR or can continue conservative
surveillance.
Current guidelines recommend AVR in patients with severe AS
and the evidence of LV decompensation based on either symptoms
or a systolic ejection fraction ,50%.19,20 However, symptoms are
often difficult to elucidate in the elderly in whom adequate exercise
stress testing may also be challenging. Furthermore, a low ejection
fraction is a late manifestation and frequently irreversible. There is
therefore considerable interest in examining novel and objective
markers of LV decompensation to identify patients who may benefit
from early AVR.1,2 The transition from hypertrophy to heart failure
in AS is driven by progressive myocyte cell death and myocardial fi-
brosis. Cardiovascular magnetic resonance is able to visualize the
latter directly, making it an attractive imaging modality to detect
early decompensation. Indeed, we and others have reported that
midwall fibrosis on CMR is not only associated with multiple fea-
tures of LV decompensation but also an adverse prognosis in pa-
tients with AS.4– 9
Unfortunately, the limited availability and relatively high costs of
CMR may make routine surveillance impractical for all patients
with AS. Consequently, a clinical score that is associated with mid-
wall fibrosis is potentially attractive, particularly one that can also
demonstrate prognostic value. In this study, we have developed
such a score consisting of variables that can easily be obtained in
routine clinical care. In addition to age, sex, and AS severity, both
high-sensitivity cTnI and ECG strain pattern were retained in the fi-
nal model as independent predictors of midwall fibrosis, consistent
with recent literature.10,11 Rather than individual determinants, an
integrated approach of using the clinical score performed best at
identifying midwall myocardial fibrosis. In particular, one cannot sim-
ply rely on the traditional markers of AS severity (such as Vmax) as
the magnitude of the hypertrophic response and the rate of LV de-
compensation are highly variable between patients.1,21–23 Although
plasma BNP concentrations were associated with midwall myocar-
dial fibrosis, the association was absent when other variables were
considered. It is likely that BNP and NT-proBNP are released in the
later stages of LV decompensation when symptoms develop and are
therefore, not sensitive markers of midwall myocardial fibrosis or
LV decompensation at an earlier state of the disease.
After the score was derived, we further established novel thresh-
olds that might risk-stratify patients according to the probability of
myocardial fibrosis. We have decided a priori to use stringent thresh-
olds to define the high- and low-risk categories in order to minimize
the false-positive and -negative rates of midwall fibrosis (,5%) and
to maximize the score’s ability to confidently identify low- and high-
risk patients.
The prognostic ability of the clinical score and associated thresh-
olds was then validated across two independent cohorts of .400
patients. To our knowledge, this is the largest validation cohort
used to test a clinical score in AS. Low-risk patients identified by
the score had a favourable prognosis: 16% of them had an AS-
related event and only one cardiovascular death over a median
time of 4.3 years. Conversely, high-risk patients had very poor out-
comes: 67% of them had either an AS-related event or died over a
median of 1.9 years, and these events occurred early. The clinical
score demonstrated similar findings regardless of age and sex, and
provided incremental prognostic information over conventional
echocardiographic assessment of AS severity. Importantly, these
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Table 5 Baseline characteristics of patients in the internal and external outcome cohorts
Internal outcome cohort (N 5 127) External outcome cohort (N5 289) P
Clinical characteristics
Age (years) 69 [62,75] 74 [67,80] ,0.001
Male, n (%) 89 (70) 209 (72) 0.88
Diabetes mellitus, n (%) 4 (3) 73 (25) ,0.001
CAD, n (%) 22 (17) 88 (30) 0.04
SBP (mmHg) 145+19 126+18 ,0.001
hsTnI concentration (ng/L) 7.6 [5.7,13.4] 7.0 [4.8,11.0] 0.03
NT-proBNP concentration (pg/mL) 198 [121,531] 169 [73,419] 0.07
ECG strain, n (%) 19 (15) 18 (6) 0.06
Echocardiography
Vmax (m/s) 3.4 [2.9,4.0] 3.0 [2.6,3.6] ,0.001
Number of patients, n (%)
,3.0 m/s 35 (27) 140 (48) ,0.001
3.0–3.9 m/s 58 (46) 109 (38)
≥4 m/s 34 (27) 40 (14)
MPG (mmHg) 24 [17,35] 21 [15,31] 0.01
AVA (cm2) 1.01 [0.72,1.28] 1.35 [1.10,1.60] ,0.001
LVMi (g/m
2) 142 [121,167] 116 [94,138] ,0.001
LVEF (%) 70 [64,78] 63 [63,68] ,0.01
For abbreviations, see Table 1.
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improvements in risk stratification were observed in patients with
moderate and severe disease.
Clinical implications
Our observations have indirectly strengthened the prognostic asso-
ciation between CMR midwall fibrosis and cardiovascular out-
comes. Potentially, asymptomatic patients with advanced AS can
initially be risk stratified using this clinical score. Patients at low
risk can be managed conservatively with regular reassessment of
risk, while those at high risk (particularly those with severe AS)
can be considered for early AVR. Finally, patients with intermedi-
ate-risk scores can undergo further risk stratification (such as
CMR to definitively assess the presence of midwall myocardial fibro-
sis, computed tomography aortic valve calcium scores, or exercise
Figure 4 Incremental prognostic value of the clinical score. In the clinical score, high-sensitivity cardiac troponin I concentrations and electro-
cardiographic strain pattern provided incremental prognostic value over and above peak aortic jet velocity, age, and sex (A). While patients at low
risk had very favourable prognosis, high-risk patients had very high event rate, regardless of sex (B and C) or median age (D and E).
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stress testing). Our risk score will therefore guide clinical manage-
ment in 25–30% of patients with AS, without the need for further
investigations. This is a cost-effective strategy to guide the timing
of AVR using more objective markers of LV decompensation. Ultim-
ately, such an approach will need to be tested in a randomized
controlled trial.
Study limitations
This study is limited by a relatively short duration of follow-up in the
external outcome cohort. Therefore, the lower mortality rates in
the external outcome cohort precluded further detailed analysis.
We had excluded patients with prior myocardial infarction from
the CMR derivation cohort so as to derive an accurate clinical score
of midwall myocardial fibrosis due to AS. Nevertheless, the findings
remained unchanged when patients with prior myocardial infarction
were included in the derivation of the score (see Supplementary
material online). Finally, CMR was not performed in the two out-
come cohorts and we were unable to reconfirm the presence of
midwall fibrosis in these patients.
Conclusions
We have developed a clinical risk score consisting of variables asso-
ciated with midwall myocardial fibrosis. This score demonstrates
strong prognostic information in asymptomatic patients with AS
and holds major potential in identifying those who may benefit
from early AVR.
Supplementary material
Supplementary material is available at European Heart Journal online.
Figure 5 Improvement in risk stratification using the clinical score in patients with moderate and severe aortic stenosis. Compared with the
natural history of patients with moderate/severe aortic stenosis (green dotted line), the clinical risk score demonstrated significant improvement in
identifying patients at low and high risk for adverse events. Furthermore, patients at intermediate risk had an event rate very similar to that prior to
risk stratification. This supported the incremental role of the clinical score over the traditional assessment of aortic stenosis severity.
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